Blood test may predict bleeding in hemophilia patients on emicizumab
NCT ID NCT04472169
First seen May 21, 2026 · Last updated May 24, 2026 · Updated 1 time
Summary
This study looks at whether checking the amount of emicizumab in the blood can help predict the risk of bleeding in people with severe hemophilia A. Researchers will follow 100 adults and children who are already taking emicizumab and track any bleeding events over about a year. The goal is to see if a special lab test (UPLC-MS/MS) can identify who is at higher risk for bleeds, which could lead to better personalized care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Caen
Caen, France
-
Institut Coeur-Poumon, Pôle d'Hématologie-Transfusion, CHU
Lille, 59037, France
Conditions
Explore the condition pages connected to this study.